USPSTF: Refer Children With High BMI to Behavioral Interventions
2024-06-18
TUESDAY, June 18, 2024 -- The U.S Preventive Services Task Force (USPSTF) recommends that clinicians refer children aged 6 years or older with a high body mass index (BMI) to comprehensive intensive behavioral interventions. These recommendations form the basis of a final recommendation statement published online June 18 in the Journal of the American Medical Association.
Elizabeth A. O'Connor, Ph.D., from the Kaiser Permanente Evidence-based Practice Center in Portland, Oregon, and colleagues examined the benefits and harms of weight management interventions initiated in health care settings among children aged 2 to 18 years with high BMI. Data were included from 58 randomized clinical trials with 10,143 participants. The researchers found that after six to 12 months, behavioral interventions were associated with small reductions in BMI and other weight outcomes. In interventions with higher contact hours and that offered physical activity sessions, larger effects were seen. For outcomes other than BMI, reporting was sparse, with few significant findings. The largest effect on BMI was seen for semaglutide and phentermine/topiramate. The few studies that assessed outcomes after discontinuation of medication showed immediate weight regain.
Based on these findings, the USPSTF concludes there is a moderate net benefit to providing or referring children and adolescents aged 6 years or older with a high BMI (≥95th percentile for age and sex) to comprehensive, intensive behavioral interventions (B recommendation).
"There are a variety of effective intensive behavioral interventions available that can help kids with a high BMI achieve a healthy weight, while improving quality of life," USPSTF member John M. Ruiz, Ph.D., said in a statement.
Evidence Report
Final Recommendation Statement
Editorial 1 (subscription or payment may be required)
Editorial 2 (subscription or payment may be required)
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。